Back to Search Start Over

Trends in pediatric donor heart discard rates and the potential use of unallocated hearts for allogeneic valve transplantation.

Authors :
Nguyen SN
Schiazza A
Richmond ME
Zuckerman WA
Bacha EA
Goldstone AB
Source :
JTCVS open [JTCVS Open] 2023 Jun 09; Vol. 15, pp. 374-381. Date of Electronic Publication: 2023 Jun 09 (Print Publication: 2023).
Publication Year :
2023

Abstract

Objectives: Allogeneic valve transplantation is an emerging therapy that delivers a living valve from a donor heart. We reviewed the national discard rate of pediatric and young adult (aged 25 years or younger) donor grafts to estimate the number of hearts potentially available to source valve allotransplantation.<br />Methods: We queried the United Network for Organ Sharing database to identify pediatric and young adult heart donors from 1987 to 2022. Donor heart discard was defined as nontransplantation of the allograft.<br />Results: Of 72,460 pediatric/young adult heart donations, 41,065 (56.7%) were transplanted and 31,395 (43.3%) were unutilized. The average annual number of discarded hearts in era 1 (1987-2000), era 2 (2000-2010), and era 3 (2010-2022) was 791 (42.8%), 1035 (46.3%), and 843 (41.2%), respectively. From 2017 to 2021, the average annual number of discards by age was: 39 (31.8%) neonates/infants, 78 (38.0%) toddlers, 41 (49.4%) young children, 240 (38.0%) adolescents, and 498 (40.1%) young adults. High-volume procurement regions had the greatest proportion of nonutilization, with the national average discard rate ranging from 39% to 49%. The most frequently documented reasons for nonallocation were distribution to the heart valve industry (26.5%), presumably due to suboptimal graft function, poor organ function (22.7%), and logistical challenges (10.8%).<br />Conclusions: With ∼900 pediatric/young adult donor hearts discarded annually, unutilized grafts represent a potential source of valves for allogeneic valve transplant to supplement current conduit and valve replacement surgery. The limited availability of neonatal and infant hearts may limit this technique in the youngest patients, for whom cryopreserved homografts or xenografts will likely remain the primary valve substitute.<br /> (© 2023 The Author(s).)

Details

Language :
English
ISSN :
2666-2736
Volume :
15
Database :
MEDLINE
Journal :
JTCVS open
Publication Type :
Academic Journal
Accession number :
37808067
Full Text :
https://doi.org/10.1016/j.xjon.2023.06.002